ASX:IMUImugene Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Imugene Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.03 0.00 (0.00 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.03Now: A$0.03▼A$0.0350-Day RangeA$0.03MA: A$0.03▼A$0.0352-Week RangeA$0.02Now: A$0.03▼A$0.06Volume12.70 million shsAverage VolumeN/AMarket Capitalization$132.78 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlines Imugene Limited, an immuno-oncology biopharmaceutical company, develops mimotopes and small molecule drug candidates in Australia. Its lead product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu receptors, which are expressed on the surface of tumors, including gastric, breast, ovarian, and pancreatic cancers. The company's HER-Vaxx has completed a Phase I clinical trial to treat breast cancer, as well as in Phase Ib/II study for gastric cancer. It has an agreement with the Baker IDI Heart & Diabetes Institute to research, develop, and commercialize a portfolio of small molecule arginine modulators for oncology. The company is based in Carlton, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Imugene. Previous Next 2.8 Community Rank Outperform VotesImugene has received 26 “outperform” votes. (Add your “outperform” vote.)Underperform VotesImugene has received 20 “underperform” votes. (Add your “underperform” vote.)Community SentimentImugene has received 56.52% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Imugene and other stocks. Vote “Outperform” if you believe IMU will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMU will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldImugene does not currently pay a dividend.Dividend GrowthImugene does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Imugene insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Imugene is -15.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Imugene is -15.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImugene has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.56 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:IMU Previous Symbol CUSIPN/A CIKN/A Webwww.imugene.com Phone61 3 9824 5254Debt Debt-to-Equity Ratio0.15 Current Ratio12.78 Quick Ratio12.59Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.88 million Price / Sales27.23 Cash FlowA$0.01 per share Price / Cash Flow3.75 Book ValueA$0.02 per share Price / Book2.00Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares4,425,970,176Market Cap$132.78 million Next Earnings DateN/A OptionableNot Optionable Receive IMU News and Ratings via Email Sign-up to receive the latest news and ratings for IMU and its competitors with MarketBeat's FREE daily newsletter. Imugene (ASX:IMU) Frequently Asked Questions How has Imugene's stock been impacted by COVID-19 (Coronavirus)? Imugene's stock was trading at A$0.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IMU shares have increased by 36.4% and is now trading at A$0.03. View which stocks have been most impacted by Coronavirus. How were Imugene's earnings last quarter? Imugene Limited (ASX:IMU) released its quarterly earnings results on Thursday, February, 28th. The company reported $0.00 EPS for the quarter. View Imugene's earnings history. Has Imugene been receiving favorable news coverage? Media headlines about IMU stock have trended neutral this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Imugene earned a daily sentiment score of 0.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Imugene. Who are some of Imugene's key competitors? Some companies that are related to Imugene include Paradigm Biopharmaceuticals (PAR), SIGA Technologies (SIGA), Biotest (BIO), Neptune Wellness Solutions (NEPT), TELIX Pharmaceutical (TLX), Starpharma (SPL), Silence Therapeutics (SLN), Altimmune (ALT), ProMetic Life Sciences (PLI), Pfenex (PFNX), IMV (IMV), Emblem (EMC), Medicenna Therapeutics (MDNA), Ergomed (ERGO) and Fennec Pharmaceuticals (FRX). View all competitors. What other stocks do shareholders of Imugene own? Based on aggregate information from My MarketBeat watchlists, some companies that other Imugene investors own include Moleculin Biotech (MBRX), Mustang Bio (MBIO), Leap Therapeutics (LPTX), LightPath Technologies (LPTH), Jaguar Health (JAGX), Groupon (GRPN), New Concept Energy (GBR), Fortescue Metals Group (FMG), Diffusion Pharmaceuticals (DFFN) and Atossa Genetics (ATOS). Who are Imugene's key executives? Imugene's management team includes the following people: Mr. Paul Edward Alexander Hopper, Exec. Chairman (Age 63)Ms. Leslie Chong, CEO, MD & Exec. DirectorDr. Nicholas J. Ede, Chief Technology OfficerMr. Phillip Allen Hains, CFO & Joint Company Sec. (Age 60)Dr. Mark T. Marino, Chief Medical Officer (Age 59) What is Imugene's stock symbol? Imugene trades on the ASX under the ticker symbol "IMU." What is Imugene's stock price today? One share of IMU stock can currently be purchased for approximately A$0.03. How big of a company is Imugene? Imugene has a market capitalization of $132.78 million and generates $4.88 million in revenue each year. What is Imugene's official website? The official website for Imugene is www.imugene.com. How can I contact Imugene? The company can be reached via phone at 61 3 9824 5254. This page was last updated on 7/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
